• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基线[F]FDG PET/CT的代谢、体积和纹理参数在早期三阴性乳腺癌中的预后价值

Prognostic Value of Metabolic, Volumetric and Textural Parameters of Baseline [F]FDG PET/CT in Early Triple-Negative Breast Cancer.

作者信息

Bouron Clément, Mathie Clara, Seegers Valérie, Morel Olivier, Jézéquel Pascal, Lasla Hamza, Guillerminet Camille, Girault Sylvie, Lacombe Marie, Sher Avigaelle, Lacoeuille Franck, Patsouris Anne, Testard Aude

机构信息

Department of Nuclear Medicine, ICO Pays de la Loire, 15 rue André Boquel, 49055 Angers, France.

Department of Nuclear Medicine, University Hospital of Angers, 4 rue Larrey, 49100 Angers, France.

出版信息

Cancers (Basel). 2022 Jan 27;14(3):637. doi: 10.3390/cancers14030637.

DOI:10.3390/cancers14030637
PMID:35158904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8833829/
Abstract

(1) Background: triple-negative breast cancer (TNBC) remains a clinical and therapeutic challenge primarily affecting young women with poor prognosis. TNBC is currently treated as a single entity but presents a very diverse profile in terms of prognosis and response to treatment. Positron emission tomography/computed tomography (PET/CT) with F-fluorodeoxyglucose ([F]FDG) is gaining importance for the staging of breast cancers. TNBCs often show high [F]FDG uptake and some studies have suggested a prognostic value for metabolic and volumetric parameters, but no study to our knowledge has examined textural features in TNBC. The objective of this study was to evaluate the association between metabolic, volumetric and textural parameters measured at the initial [F]FDG PET/CT and disease-free survival (DFS) and overall survival (OS) in patients with nonmetastatic TBNC. (2) Methods: all consecutive nonmetastatic TNBC patients who underwent a [F]FDG PET/CT examination upon diagnosis between 2012 and 2018 were retrospectively included. The metabolic and volumetric parameters (SUV, SUV, SUV, MTV, and TLG) and the textural features (entropy, homogeneity, SRE, LRE, LGZE, and HGZE) of the primary tumor were collected. (3) Results: 111 patients were enrolled (median follow-up: 53.6 months). In the univariate analysis, high TLG, MTV and entropy values of the primary tumor were associated with lower DFS ( = 0.008, = 0.006 and = 0.025, respectively) and lower OS ( = 0.002, = 0.001 and = 0.046, respectively). The discriminating thresholds for two-year DFS were calculated as 7.5 for MTV, 55.8 for TLG and 2.6 for entropy. The discriminating thresholds for two-year OS were calculated as 9.3 for MTV, 57.4 for TLG and 2.67 for entropy. In the multivariate analysis, lymph node involvement in PET/CT was associated with lower DFS ( = 0.036), and the high MTV of the primary tumor was correlated with lower OS ( = 0.014). (4) Conclusions: textural features associated with metabolic and volumetric parameters of baseline [F]FDG PET/CT have a prognostic value for identifying high-relapse-risk groups in early TNBC patients.

摘要

(1) 背景:三阴性乳腺癌(TNBC)仍然是一项临床和治疗挑战,主要影响预后较差的年轻女性。TNBC目前被视为一个单一实体,但在预后和对治疗的反应方面呈现出非常多样化的特征。使用F-氟脱氧葡萄糖([F]FDG)的正电子发射断层扫描/计算机断层扫描(PET/CT)在乳腺癌分期中越来越重要。TNBC通常表现出高[F]FDG摄取,一些研究表明代谢和体积参数具有预后价值,但据我们所知,尚无研究检查TNBC的纹理特征。本研究的目的是评估在初始[F]FDG PET/CT测量的代谢、体积和纹理参数与非转移性TBNC患者的无病生存期(DFS)和总生存期(OS)之间的关联。(2) 方法:回顾性纳入2012年至2018年间所有在诊断时接受[F]FDG PET/CT检查的连续非转移性TNBC患者。收集原发肿瘤的代谢和体积参数(SUV、SUV、SUV、MTV和TLG)以及纹理特征(熵、均匀性、SRE、LRE、LGZE和HGZE)。(3) 结果:共纳入111例患者(中位随访时间:53.6个月)。在单因素分析中,原发肿瘤的高TLG、MTV和熵值与较低的DFS(分别为 = 0.008、 = 0.006和 = 0.025)和较低的OS(分别为 = 0.002、 = 0.001和 = 0.046)相关。两年DFS的鉴别阈值计算为MTV为7.5、TLG为55.8、熵为2.6。两年OS的鉴别阈值计算为MTV为9.3、TLG为57.4、熵为2.67。在多因素分析中,PET/CT中的淋巴结受累与较低的DFS相关( = 0.036),原发肿瘤的高MTV与较低的OS相关( = 0.014)。(4) 结论:与基线[F]FDG PET/CT的代谢和体积参数相关的纹理特征对识别早期TNBC患者中的高复发风险组具有预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/0457affe119d/cancers-14-00637-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/82379290f7f8/cancers-14-00637-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/9dd4dd9e8770/cancers-14-00637-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/0e3a4175ccea/cancers-14-00637-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/a71109233413/cancers-14-00637-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/e8cbb0fdb708/cancers-14-00637-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/7381d4908390/cancers-14-00637-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/9b7555ae0157/cancers-14-00637-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/edcb5455ad62/cancers-14-00637-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/66e8a4cecfa3/cancers-14-00637-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/0457affe119d/cancers-14-00637-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/82379290f7f8/cancers-14-00637-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/9dd4dd9e8770/cancers-14-00637-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/0e3a4175ccea/cancers-14-00637-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/a71109233413/cancers-14-00637-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/e8cbb0fdb708/cancers-14-00637-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/7381d4908390/cancers-14-00637-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/9b7555ae0157/cancers-14-00637-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/edcb5455ad62/cancers-14-00637-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/66e8a4cecfa3/cancers-14-00637-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/088f/8833829/0457affe119d/cancers-14-00637-g010.jpg

相似文献

1
Prognostic Value of Metabolic, Volumetric and Textural Parameters of Baseline [F]FDG PET/CT in Early Triple-Negative Breast Cancer.基线[F]FDG PET/CT的代谢、体积和纹理参数在早期三阴性乳腺癌中的预后价值
Cancers (Basel). 2022 Jan 27;14(3):637. doi: 10.3390/cancers14030637.
2
Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from F-FDG PET/CT in operable triple-negative breast cancer.使用 F-FDG PET/CT 检测可手术的三阴性乳腺癌腋窝淋巴结代谢和容积参数预测乳腺癌复发。
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1787-1795. doi: 10.1007/s00259-017-3748-7. Epub 2017 Jun 14.
3
Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.标准化摄取值和代谢肿瘤体积在¹⁸F-FDG PET/CT上对口咽鳞状细胞癌的预后意义
Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1353-61. doi: 10.1007/s00259-015-3051-4. Epub 2015 Jun 12.
4
Evaluation of the Prognostic Value of FDG PET/CT Parameters for Patients With Surgically Treated Head and Neck Cancer: A Systematic Review.评估 FDG PET/CT 参数对手术治疗头颈部癌症患者预后的价值:系统评价。
JAMA Otolaryngol Head Neck Surg. 2020 May 1;146(5):471-479. doi: 10.1001/jamaoto.2020.0014.
5
Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.术前FDG-PET/CT代谢和容积参数对可切除胰腺癌患者的预后价值
Medicine (Baltimore). 2016 May;95(19):e3686. doi: 10.1097/MD.0000000000003686.
6
The Value of Semiquantitative Parameters Derived from F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer.源自F-FDG PET/CT的半定量参数对不同分子亚型乳腺癌患者新辅助化疗反应的预测价值
Cancers (Basel). 2022 Nov 29;14(23):5869. doi: 10.3390/cancers14235869.
7
The prognostic value of F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases.移植前行 F-FDG PET/CT 对不可切除结直肠癌肝转移的预后价值。
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):218-225. doi: 10.1007/s00259-017-3843-9. Epub 2017 Oct 12.
8
Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline F-FDG PET/CT in breast cancer with neoadjuvant chemotherapy indication.基线F-FDG PET/CT获得的基于体积的代谢变量在有新辅助化疗指征的乳腺癌中的预测和预后潜力。
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Mar-Apr;37(2):73-79. doi: 10.1016/j.remn.2017.09.002. Epub 2017 Nov 2.
9
The Role of the Metabolic Parameters of F-FDG PET/CT in Patients With Locally Advanced Cervical Cancer.F-FDG PET/CT代谢参数在局部晚期宫颈癌患者中的作用
Front Oncol. 2021 Aug 19;11:698744. doi: 10.3389/fonc.2021.698744. eCollection 2021.
10
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.预处理代谢肿瘤体积和 18F-FDG PET/CT 总病变糖酵解对接受抗血管内皮生长因子靶向药物治疗的转移性肾细胞癌患者的预后价值。
Clin Nucl Med. 2017 May;42(5):e235-e241. doi: 10.1097/RLU.0000000000001612.

引用本文的文献

1
Cross-Sectional Analysis of Metabolic Tumor Burden Detected by F-18 FDG PET/CT and Circulating Tumor DNA in Advanced Breast Cancer.F-18 FDG PET/CT检测的代谢肿瘤负荷与晚期乳腺癌循环肿瘤DNA的横断面分析
Cancer Med. 2025 Aug;14(16):e71049. doi: 10.1002/cam4.71049.
2
18F-FDG PET/CT Semiquantitative and Radiomic Features for Assessing Pathologic Axillary Lymph Node Status in Clinical Stage I-III Breast Cancer Patients: A Systematic Review.18F-FDG PET/CT半定量和影像组学特征用于评估临床I-III期乳腺癌患者腋窝病理淋巴结状态:一项系统综述
Curr Oncol. 2025 May 23;32(6):300. doi: 10.3390/curroncol32060300.
3
Evaluation of prognostic risk factors of triple-negative breast cancer with F-FDG PET/CT parameters, clinical pathological features and biochemical indicators.

本文引用的文献

1
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.三阴性乳腺癌新辅助化疗疗效的 co-clinical FDG-PET 影像组学特征。
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):550-562. doi: 10.1007/s00259-021-05489-8. Epub 2021 Jul 30.
2
Multiparametric Integrated F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding.基于多参数整合F-FDG PET/MRI的影像组学用于乳腺癌表型分析和肿瘤解码
Cancers (Basel). 2021 Jun 11;13(12):2928. doi: 10.3390/cancers13122928.
3
Breast Tumor Characterization Using [F]FDG-PET/CT Imaging Combined with Data Preprocessing and Radiomics.
基于F-FDG PET/CT参数、临床病理特征及生化指标评估三阴性乳腺癌的预后危险因素
Front Cell Dev Biol. 2024 Sep 4;12:1421981. doi: 10.3389/fcell.2024.1421981. eCollection 2024.
4
The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.PET 成像对三阴性乳腺癌的影响:基于循证的最新观点。
Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):263-279. doi: 10.1007/s00259-024-06866-9. Epub 2024 Aug 7.
5
Baseline [F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy.基线 [F]FDG PET/CT 和 MRI 一级乳腺癌肿瘤特征不能改善新辅助化疗的病理完全缓解预测。
Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3709-3718. doi: 10.1007/s00259-024-06815-6. Epub 2024 Jun 26.
6
Head-to-Head Comparison of [F]PSMA-1007 and [F]FDG PET/CT in Patients with Triple-Negative Breast Cancer.[F]PSMA - 1007与[F]FDG PET/CT在三阴性乳腺癌患者中的头对头比较
Cancers (Basel). 2024 Feb 4;16(3):667. doi: 10.3390/cancers16030667.
7
Elevated splenic 18F-fluorodeoxyglucose positron emission tomography/computed tomography activity is associated with 5-year risk of recurrence in non-metastatic invasive ductal carcinoma of the breast.脾脏 18F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描活性升高与非转移性浸润性乳腺癌 5 年复发风险相关。
Br J Radiol. 2024 Jan 23;97(1153):237-248. doi: 10.1093/bjr/tqad015.
8
F-FDG PET/CT-based deep learning radiomics predicts 5-years disease-free survival after failure to achieve pathologic complete response to neoadjuvant chemotherapy in breast cancer.基于F-FDG PET/CT的深度学习影像组学可预测乳腺癌新辅助化疗未达到病理完全缓解后的5年无病生存率。
EJNMMI Res. 2023 Dec 6;13(1):105. doi: 10.1186/s13550-023-01053-7.
9
Dynamic 2-deoxy-D-glucose-enhanced multispectral optoacoustic tomography for assessing metabolism and vascular hemodynamics of breast cancer.动态2-脱氧-D-葡萄糖增强多光谱光声断层成像用于评估乳腺癌的代谢和血管血流动力学
Photoacoustics. 2023 Jul 9;32:100531. doi: 10.1016/j.pacs.2023.100531. eCollection 2023 Aug.
10
The Efficacy of Pretreatment F-FDG PET-CT-Based Deep Learning Network Structure to Predict Survival in Nasopharyngeal Carcinoma.基于预处理F-FDG PET-CT的深度学习网络结构预测鼻咽癌生存的疗效
Clin Med Insights Oncol. 2023 May 23;17:11795549231171793. doi: 10.1177/11795549231171793. eCollection 2023.
使用[F]FDG-PET/CT成像结合数据预处理和放射组学对乳腺肿瘤进行特征描述
Cancers (Basel). 2021 Mar 12;13(6):1249. doi: 10.3390/cancers13061249.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Prognostic value of metabolic tumor volume and total lesion glycolysis in breast cancer: a meta-analysis.代谢肿瘤体积和总病变糖酵解在乳腺癌中的预后价值:一项荟萃分析。
Nucl Med Commun. 2020 Aug;41(8):824-829. doi: 10.1097/MNM.0000000000001227.
6
Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)中的纹理特征可以预测黑色素瘤患者接受维莫非尼和伊匹单抗治疗的结果。
Nuklearmedizin. 2020 Jun;59(3):228-234. doi: 10.1055/a-1140-5458. Epub 2020 Apr 7.
7
F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients.乳腺癌患者新辅助化疗病理完全缓解(pCR)的F-FDG PET/CT影像组学预测指标
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1116-1126. doi: 10.1007/s00259-020-04684-3. Epub 2020 Jan 25.
8
Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with breast cancer: A systematic review and meta-analysis.正电子发射断层扫描/计算机断层扫描最大标准摄取值、代谢肿瘤体积和总病灶糖酵解在乳腺癌患者中的预后价值:系统评价和荟萃分析。
PLoS One. 2019 Dec 11;14(12):e0225959. doi: 10.1371/journal.pone.0225959. eCollection 2019.
9
Heterogeneity in tumours: Validating the use of radiomic features on F-FDG PET/CT scans of lung cancer patients as a prognostic tool.肿瘤异质性:验证使用肺癌患者 F-FDG PET/CT 扫描的放射组学特征作为预后工具的有效性。
Radiother Oncol. 2020 Mar;144:72-78. doi: 10.1016/j.radonc.2019.10.012. Epub 2019 Nov 14.
10
Prognostic Significance of Metabolic Parameters and Textural Features on F-FDG PET/CT in Invasive Ductal Carcinoma of Breast.代谢参数和纹理特征在 F-FDG PET/CT 对乳腺浸润性导管癌的预后意义。
Sci Rep. 2019 Jul 29;9(1):10946. doi: 10.1038/s41598-019-46813-5.